(Total Views: 847)
Posted On: 02/15/2021 4:43:43 PM
Post# of 155793
What a great opportunity to explore all the concomitant benefits of leronlimab in say, a million patients treated for Covid! What a huge bioinformatics project this would be, sorting through all the diseases on Ohm's list!
But first we have to get the data. That concern generated an Idea I haven't seen discussed before regarding the key obstacles to CytoDyn's growth:
When the stock price hits $25 or so, why don't we buy out the world's best CRO with some pocket change? A paper that ranks them is linked below.
Jumping on data acquisition from our Covid "natural experiment," followed by AI so we can rank opportunities is task one, but then efficiently coordinating the resulting massive clinical research programs is step two. Of course, the CRO can keep their old business.
I think between expanding staffs for the scientific advisory board members and buying in the skill sets of a superior CRO, a good fraction of CytoDyn's need for growth in skills and scope could be addressed.
https://www.worldwide.com/cro-quality-ranking...URL=Google
But first we have to get the data. That concern generated an Idea I haven't seen discussed before regarding the key obstacles to CytoDyn's growth:
When the stock price hits $25 or so, why don't we buy out the world's best CRO with some pocket change? A paper that ranks them is linked below.
Jumping on data acquisition from our Covid "natural experiment," followed by AI so we can rank opportunities is task one, but then efficiently coordinating the resulting massive clinical research programs is step two. Of course, the CRO can keep their old business.
I think between expanding staffs for the scientific advisory board members and buying in the skill sets of a superior CRO, a good fraction of CytoDyn's need for growth in skills and scope could be addressed.
https://www.worldwide.com/cro-quality-ranking...URL=Google
(8)
(0)
